Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
In view of the fact that neoadjuvant therapy for malignant melanoma is in the exploratory
stage, and the current data on neoadjuvant immunology are mainly from European and American
populations, it is necessary to carry out clinical trials in the status of neoadjuvant
immunotherapy for patients with melanoma in China. Toripalimab has been extensively studied
in the field of malignant melanoma, and its effectiveness and safety have been proven.
Therefore, the investigators initiated a single-arm exploratory study to investigate the
efficacy and safety of Toripalimab in neoadjuvant treatment of patients with BRAF V600
wild-type malignant melanoma.